Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine Adjuvant Chemotherapy in TNBC (CBCSG010)
NCT01642771Phase 3Unknown
- Sponsor
- China Breast Cancer Clinical Study Group
- Start
- Jun 2012
- Primary completion
- Dec 2019
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in triple-negative breast cancer (TNBC) (2 arms), sponsored by China Breast Cancer Clinical Study Group. Primary endpoint: Disease Free Survival at 5 years. Status: unknown.
02
Drugs
capecitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01642771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01642771.